Analyzing RNA from blood platelets detected up to 18 different cancers, at early as well as late stages, with a specificity of 99% in asymptomatic controls. The specificity for symptomatic controls, including those who had inflammatory diseases, cardiovascular disease, or benign tumors, was 78%.
The Massachusetts Institute of Technology (MIT) has developed collagen mimetic peptides for PET imaging to detect idiopathic pulmonary fibrosis (IPF), with [68Ga]DOTA-CMP showing selective identification of fibrotic collagen in vivo.
Researchers from Baylor College of Medicine and Texas Children's Hospital detailed the discovery of CPK-03-37, a novel fluorescent organic molecule for tumor imaging.
3B Pharmaceuticals has divulged conjugates comprising fibroblast activation protein alpha (FAPalpha) inhibitors covalently linked to radiolabeled chelating agents through a linker acting as single-photon emission computed tomography (SPECT)/CT imaging agents reported to be useful for the diagnosis and treatment of cancer.